BioMarin Pharmaceutical stock received updates on July 18, 2026, including a price target boost from Citigroup, reported by Benzinga.

The entities involved

• BioMarin Pharmaceutical →

  American company

  • BioMarin Pharmaceutical and XTL Biopharmaceuticals are identified as healthcare companies competing for investment.Sun 12:39
• Benzinga →

  American news channel

  • Morgan Stanley reduced its price target on DT Midstream, while Scotiabank set a new price objective, as reported by Benzinga.07:26
  • Edward Jones dropped its price objective on Real REMAX Group, with the rating reported by Benzinga.06:00
• Citigroup →

  American investment bank and financial services corporation

  • MarketBeat reported on the merger of thyssenkrupp AG and Thyssen AG, which is receiving analyst ratings and company data.08:28
  • Crumly & Associates Inc. bought shares of Newmont Corporation, while Scotiabank, Royal Bank of Canada, and Citigroup issued various rating and price target changes.08:07

Related events

• Benzinga reported on Cirrus Logic stock, which is listed on Nasdaq, following a price target cut by Susquehanna.Wed 14:50
• Benzinga reported that Mizuho cut its target price for a stock.Oct 7
• Benzinga Pro data reports on stock activity for Webull, a company related to the Nasdaq exchange.Jul 21
• Mizuho analysts increased their price target on Amylyx Pharmaceuticals, with the news being reported by Benzinga on July 20, 2026.Jul 20
• Citigroup and Barclays lowered their price targets on Equifax stock, while MarketBeat provided a consensus rating.Wed 15:07